Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA cobimetinib Cotellic 20 mg Chemotherapy MAPK/MEK Inhibitor BRAF Yes 2015 In Use
NA Tepotinib Hydrochloride Tepmetko 225mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2021 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Pomalidomide Pomalyst 4 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Pralsetinib Gavreto 100mg Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Yes 2020 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
NA Raloxifene Hydrochloride Evista 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Nintedanib Ofev 150 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
NA Thalidomide Thalomid 100 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Enzalutamide Xtandi 40 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 2012 In Use
NA Vorinostat Erivedge 100 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2006 In Use
Repotrectinib Augtyro 40mg, 160mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2023 In Use
J8510 Busulfan Myleran 2 mg Chemotherapy Alkylating Agent Alkylsulfonate Yes 1954 Jan 1, 2000 In Use
NA Bosutinib Bosulif 500 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.625 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Palbociclib Ibrance 125 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Dostarlimab Jemperli 50mg Immunotherapy Checkpoint Inhibitor PD-1 Yes 2021 In Use
NA idelalisib Zydelig 100 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Panobinostat Farydak 20 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Rucaparib Rubraca 300 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.